A program hoping to supercharge a patient’s own immune system cells to attack and kill a treatment resistant form of prostate cancer was today awarded $3.99 million by the governing Board of the California Institute for Regenerative Medicine (CIRM) In the U.S., prostate cancer is the second most common cause of cancer deaths in men. … Continue reading Research Targeting Prostate Cancer Gets Almost $4 Million Support from CIRM
Maria Millan
CIRM invests in stem cell clinical trial targeting lung cancer and promising research into osteoporosis and incontinence
The five-year survival rate for people diagnosed with the most advanced stage of non-small cell lung cancer (NSCLC) is pretty grim, only between one and 10 percent. To address this devastating condition, the Board of the California Institute for Regenerative Medicine (CIRM) today voted to invest almost $12 million in a team from UCLA that … Continue reading CIRM invests in stem cell clinical trial targeting lung cancer and promising research into osteoporosis and incontinence
Breaking down barriers to advance stem cell therapies – the view from the Vatican conference
All hands were on deck at the “Unite to Cure” conference, organized by the Cura Foundation and the Vatican Pontifical Council, and held at the Vatican on April 26-28. Religious leaders, scientists, physicians, philanthropists, industry leaders, government, academic leaders and members of the entertainment industry gathered to discuss how to improve human health and to … Continue reading Breaking down barriers to advance stem cell therapies – the view from the Vatican conference
CIRM applauds FDA crackdown on stem cell clinics that “peddle unapproved treatments.”
CIRM is commending the US Food and Drug Administration (FDA) for its action against two stem cell clinics offering unapproved therapies. On Wednesday, the FDA filed two complaints in federal court seeking a permanent injunction against California Stem Cell Treatment Center Inc. and US Stem Cell Clinic LLC. of Sunrise, Florida. The FDA says the … Continue reading CIRM applauds FDA crackdown on stem cell clinics that “peddle unapproved treatments.”
Stem Cell Agency’s supporting role in advancing research for rare diseases
The recent agreement transferring GSK’s rare disease gene therapies to Orchard Therapeutics was good news for both companies and for the patients who are hoping this research could lead to new treatments, even cures, for some rare diseases. It was also good news for CIRM, which played a key role in helping Orchard grow to … Continue reading Stem Cell Agency’s supporting role in advancing research for rare diseases
Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost $32 Million Boost from CIRM Board
An innovative therapy that uses a patient’s own immune system to attack cancer stem cells is one of three new clinical trials approved for funding by CIRM's Governing Board. Researchers at the Stanford University School of Medicine were awarded $11.9 million to test their Chimeric Antigen Receptor (CAR) T Cell Therapy in patients with B … Continue reading Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost $32 Million Boost from CIRM Board
A road trip to the Inland Empire highlights a hot bed of stem cell research
It took us longer than it should have to pay a visit to California’s Inland Empire, but it was definitely worth the wait. Yesterday CIRM’s Roadshow went to the University of California at Riverside (UCR) to talk to the community there – both scientific and public – about the work we are funding and the … Continue reading A road trip to the Inland Empire highlights a hot bed of stem cell research
Budgeting for the future of the stem cell agency
Budgets are very rarely exciting things; but they are important. For example, it’s useful for a family to know when they go shopping exactly how much money they have so they know how much they can afford to spend. Stem cell agencies face the same constraints; you can’t spend more than you have. Last week … Continue reading Budgeting for the future of the stem cell agency
Hey, what’s the big idea? CIRM Board is putting up more than $16.4 million to find out
When you have a life-changing, life-threatening disease, medical research never moves as quickly as you want to find a new treatment. Sometimes, as in the case of Parkinson’s disease, it doesn’t seem to move at all. At our Board meeting last week David Higgins, our Board member and Patient Advocate for Parkinson’s disease, made that … Continue reading Hey, what’s the big idea? CIRM Board is putting up more than $16.4 million to find out
CIRM stories that caught our eye: UCSD team stops neuromuscular disease in mice, ALS trial enrolls 1st patients and Q&A with CIRM Prez
Ordinarily, we end each week at the Stem Cellar with a few stem cell stories that caught our eye. But, for the past couple of weeks we've been busy churning out stories related to our Month of CIRM blog series, which we hope you've found enlightening. To round out the series, we present this "caught … Continue reading CIRM stories that caught our eye: UCSD team stops neuromuscular disease in mice, ALS trial enrolls 1st patients and Q&A with CIRM Prez
The Stem Cellar 